UM

Browse/Search Results:  1-3 of 3 Help

Selected(0)Clear Items/Page:    Sort:
Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors Journal article
Zou, Huimin, Ge, Ying, Chen, Wenge, Yao, Dongning, Oi Lam Ung, Carolina, Lai, Yunfeng, Hu, Hao. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors[J]. International Immunopharmacology, 2024, 132, 111947.
Authors:  Zou, Huimin;  Ge, Ying;  Chen, Wenge;  Yao, Dongning;  Oi Lam Ung, Carolina; et al.
Favorite | TC[WOS]:0 TC[Scopus]:1  IF:4.8/5.0 | Submit date:2024/05/16
Hepatocellular Carcinoma  Programmed Cell Death Protein-1 Inhibitor  Tislelizumab  Camrelizumab  China  
An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects Journal article
Zhao, Long, Luo, Hao, Ma, Yu, Zhu, Shengze, Wu, Yongjiang, Lu, Muxing, Yao, Xiaojun, Liu, Xin, Chen, Gang. An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects[J]. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119(31).
Authors:  Zhao, Long;  Luo, Hao;  Ma, Yu;  Zhu, Shengze;  Wu, Yongjiang; et al.
Favorite | TC[WOS]:11 TC[Scopus]:13  IF:9.4/10.8 | Submit date:2023/01/30
Analgesic  Chronic Pain  Dorsal Root Ganglion  Programmed Cell Death Protein 1  Src Homology 2 Domain–containing Tyrosine Phosphatase 1  
Targeting PD-L1 Protein: Translation, Modification and Transport Journal article
Wei R., Guo L., Wang Q., Miao J., Kwok H.F., Lin Y.. Targeting PD-L1 Protein: Translation, Modification and Transport[J]. Current protein & peptide science, 2019, 20(1), 82-91.
Authors:  Wei R.;  Guo L.;  Wang Q.;  Miao J.;  Kwok H.F.; et al.
Favorite | TC[WOS]:22 TC[Scopus]:23  IF:1.9/3.0 | Submit date:2018/12/19
Immunotherapy  Modification  Programmed Cell Death Protein 1 (Pd-1)  Programmed Death Ligand 1 (Pd-l1)  Translation  Transport.